JAMA Psychiatry

Rising concerns over prescription stimulant misuse among U.S. adults

March 24, 2025

Study design: This cross-sectional survey study utilized data from the 2019-2022 IQVIA Total Patient Tracker and National Prescription Audit New to Brand databases, along with the 2021-2022 National Surveys on Drug Use and Health. The study population included community-dwelling adults aged 18 to 64 years, with data analysis performed from March to April 2024.

Results: Among 83,762 adults, 25.3% of those using prescription stimulants reported misuse, and 9.0% had prescription stimulant use disorder (PSUD). Amphetamine users had higher prevalence ratios of misuse (3.1) and PSUD (2.2) compared with methylphenidate users. The largest increase in stimulant prescriptions was observed in women aged 35 to 64 years. Misuse prevalence was lower in this group (13.7%) compared with other subgroups.

Clinical impact: The high prevalence of misuse and PSUD underscores the need for clinicians to ensure appropriate use and to screen for PSUD, particularly among amphetamine users. Findings highlight the importance of evidence-based clinical guidance and training on the risks and benefits of prescription stimulants for adults.

Source:

Han B, et al. (2025, March 19). JAMA Psychiatry. Prescription Stimulant Use, Misuse, and Use Disorder Among US Adults Aged 18 to 64 Years. https://pubmed.ncbi.nlm.nih.gov/40105821/